PDS Biotech Plunges 67% After Scrapping Lead Cancer Trial, Pivoting to Colorectal Program
PDSB is trading near its 52-week low of $0.231 (6.8% above the low) on elevated volume (23× avg).
Summary
PDS Biotech is discontinuing its Phase 3 VERSATILE-003 trial for PDS0101, its lead asset, and redirecting resources to PDS0301 for metastatic colorectal cancer. The company cited a more attractive path to shareholder value with PDS0301's clinical data and capital requirements. The market is punishing the stock, down ~67% to $0.26, a new 52-week low, with RSI at 17.90 indicating deeply oversold conditions. This follows a July 31 Nasdaq deficiency notice for falling below the $1.00 minimum bid price, and the company now faces a delisting clock with a sub-$0.30 share price. The strategic refocus was announced earlier today, but the severity of the sell-off and technical breakdown are new developments that demand immediate attention.
At the time of this announcement, PDSB was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.9M. The 52-week trading range was $0.23 to $1.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.